<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650401</url>
  </required_header>
  <id_info>
    <org_study_id>RXDX-101-03</org_study_id>
    <nct_id>NCT02650401</nct_id>
  </id_info>
  <brief_title>Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions</brief_title>
  <official_title>A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX 101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ignyta, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ignyta, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 5-part, open-label, Phase 1/1b multicenter, dose escalation study in pediatric
      patients with relapsed refractory solid tumors; 2) primary CNS tumors; 3) neuroblastoma; 4)
      non-neuroblastoma, extracranial solid tumors with NTRK1/2/3, ROS1 or ALK gene rearrangements;
      and 5) patients who are otherwise eligible but unable to swallow capsules. The study is
      designed to explore the safety, maximum tolerated dose (MTD) or recommended Phase 2 dose
      (RP2D), pharmacokinetics, and antitumor activity of entrectinib.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Assessed by NCI CTCAE v4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>AE, ECG and Labs assessed by NCI CTCAE v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma drug concentration (Cmax)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Assessed by plasma concentrations obtained Day 1 (Cycles 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax, by inspection (Tmax)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Assessed by plasma concentrations obtained Day 1 (Cycles 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Assessed by plasma concentrations obtained Day 1 (Cycles 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half life (t½)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Assessed by plasma concentrations obtained Day 1 (Cycles 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the drug concentration by time curve (AUC)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Assessed by plasma concentrations obtained Day 1 (Cycles 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Defined as time from the date of study enrollment to the first occurrence of objective disease progression or date of death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Solid Tumors</condition>
  <condition>CNS Tumors</condition>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Extracranial solid tumors harboring NTRK1/2/3,</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ROS1, ALK non-gene fusion molecular alterations
Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNS tumors harboring- NTRK1/2/3, ROS1, ALK</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>molecular alterations, including gene fusions
Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neuroblastoma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-neuroblastoma, extracranial solid tumors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>harboring - NTRK1/2/3, ROS1, ALK gene fusions
Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Any patient unable to swallow capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>who otherwise meet all other eligibility criteria
Oral entrectinib (RXDX-101)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entrectinib</intervention_name>
    <description>TRKA/B/C, ROS1, and ALK inhibitor</description>
    <arm_group_label>Extracranial solid tumors harboring NTRK1/2/3,</arm_group_label>
    <arm_group_label>CNS tumors harboring- NTRK1/2/3, ROS1, ALK</arm_group_label>
    <arm_group_label>Neuroblastoma</arm_group_label>
    <arm_group_label>Non-neuroblastoma, extracranial solid tumors</arm_group_label>
    <arm_group_label>Any patient unable to swallow capsules</arm_group_label>
    <other_name>RXDX-101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to swallow capsules unless enrolled in Part E

          2. Body surface area (BSA): Subjects must have a body surface area ≥ 0.45 m2 at the time
             of the study enrollment, unless enrolled in Part E

          3. Disease status: Subjects must have measurable or evaluable disease, by RECIST v1.1 ±
             Curie Scale Criteria or RANO/RANO-BM

          4. Tumor type:

               -  Part A: Relapsed or refractory extracranial solid tumors and (Phase 1b expansion)
                  relapsed or refractory extracranial solid tumors with molecular alterations,
                  non-gene fusions;

               -  Part B: Relapsed or refractory primary CNS tumors with molecular alterations,
                  including gene fusions, documented by a CLIA-approved lab prior to enrollment;

               -  Part C: Relapsed or refractory neuroblastoma;

               -  Part D: Relapsed or refractory non-neuroblastoma, extracranial solid tumors with
                  NTRK1/2/3, ROS1, or ALK gene fusions documented by a CLIA-approved lab prior to
                  enrollment;

               -  Part E: Any patient unable to swallow capsules who otherwise meet all other
                  eligibility criteria for Part A (expansion) B, C or D

          5. Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse

          6. Archival tumor tissue from diagnosis or, preferably, at relapse

          7. Age: Male or female age ≥ 2 years and &lt; 22 years unless enrolled in Part E

          8. Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at
             least 4 weeks

          9. Patient's cancer must have relapsed after or failed to respond to frontline curative
             therapy or there must not be other potentially curative treatment options available

         10. Adequate organ and neurologic function

         11. Females of child bearing potential must have a negative serum pregnancy test within 14
             days prior to entrectinib dosing

        Exclusion Criteria:

          1. Receiving other experimental therapy

          2. Known congenital long QT syndrome

          3. Known active infections

          4. Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.

          5. Incomplete recovery from acute effects of any surgery prior to treatment.

          6. Active gastrointestinal disease or other malabsorption syndromes that would impact
             drug absorption.

          7. Other severe acute or chronic medical or psychiatric condition or lab abnormality that
             may increase the risk associated with study participation, drug administration or may
             interfere with the interpretation of study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edna Chow Maneval, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ignyta, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanessa Esquibel</last_name>
    <phone>(858) 255-5959</phone>
    <phone_ext>230</phone_ext>
    <email>vesquibel@ignyta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorian Chan</last_name>
      <phone>714-509-7868</phone>
      <email>DChan@choc.org</email>
    </contact>
    <investigator>
      <last_name>Elyssa Rubin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Janet Yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Benihoff Children's</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Schwartz</last_name>
      <phone>415-476-4923</phone>
      <email>stephanie.schwartz@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Amit Sabnis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Schissel</last_name>
      <phone>720-777-2879</phone>
      <email>debra.schissel@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Margaret Macy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kane Kaosaard</last_name>
      <phone>202-476-2800</phone>
      <email>KKAOSAARD2@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Holly Meany, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Smith</last_name>
      <phone>404-785-0692</phone>
      <email>Jaclyn.smith@choa.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Cash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saki Nishi, CCRP</last_name>
      <phone>773-702-1762</phone>
      <email>snishi@peds.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Ami Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John's Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Courneya</last_name>
      <phone>443-287-3968</phone>
      <email>jcourne2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Christine Pratilas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Carlowicz</last_name>
      <phone>617-632-4931</phone>
      <email>ccarlowicz@partners.org</email>
    </contact>
    <investigator>
      <last_name>Suzanne Shusterman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emily Greengard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Univ School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Martin</last_name>
      <phone>314-454-4962</phone>
      <email>martin.g@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Karen Gauvain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Univ Ped Hem/Onc</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etleva Haxhiymeri</last_name>
      <phone>212-305-0625</phone>
      <email>eh2739@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Julia Glade Bender, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julianne Cameron</last_name>
      <phone>646-888-5717</phone>
      <email>cameronj@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Ellen Basu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Backus</last_name>
      <phone>513-517-0607</phone>
      <email>lori.backus@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Brian Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Ott</last_name>
      <phone>614-722-6313</phone>
      <email>kristy.ott@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Mohamad S. AdbelBaki, MD, NeuroOnc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AiLien Truong</last_name>
      <phone>503-418-2394</phone>
      <email>truonga@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Rebecca Loret De Mola, DO, MCR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Gottschalk</last_name>
      <phone>267-426-9293</phone>
      <phone_ext>69293</phone_ext>
    </contact>
    <investigator>
      <last_name>Elizabeth Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Pranica, RN</last_name>
      <phone>901-595-5787</phone>
      <email>johanna.pranica@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Amar Gajjar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Hospital</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Stone, RN, BSN, CCRC</last_name>
      <email>Leah.Stone@cookchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Kelly Vallance, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer, Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Klenke</last_name>
      <phone>832-824-4646</phone>
      <email>raklenke@txch.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer Foster, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ of Utah, Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taylor Shuman</last_name>
      <email>Taylor.Shuman@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Luke Maese, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TRK</keyword>
  <keyword>Tyrosine kinase</keyword>
  <keyword>NTRK</keyword>
  <keyword>NTRK1</keyword>
  <keyword>NTRK2</keyword>
  <keyword>NTRK3</keyword>
  <keyword>ROS1</keyword>
  <keyword>ALK</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Gene rearrangement</keyword>
  <keyword>Neuroblastoma</keyword>
  <keyword>Infantile fibrosarcoma</keyword>
  <keyword>Secretory breast cancer</keyword>
  <keyword>Congenital mesoblastic nephroma</keyword>
  <keyword>Pontine glioma</keyword>
  <keyword>Brain tumors</keyword>
  <keyword>CNS tumors</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Ewing sarcoma</keyword>
  <keyword>Glial tumors</keyword>
  <keyword>Salivary Gland Cancer (MASC)</keyword>
  <keyword>Papillary thyroid cancer</keyword>
  <keyword>Medulloblastoma</keyword>
  <keyword>Wilms tumor (anaplastic)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

